Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

Aug 1, 2019

Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results

Jun 24, 2019

Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock

Jun 18, 2019

Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study

Jun 17, 2019

Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

Jun 13, 2019

Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock

Jun 13, 2019

Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

Jun 13, 2019

Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

May 8, 2019

Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

May 1, 2019

Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)

Apr 26, 2019